Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Clinical Data

Maze tumbles despite positive data for kidney disease drug

 March 25, 2026

BioPharma Dive

Investors had reservations about data for a drug that could compete with a candidate from Vertex in APOL1-mediated kidney disease.

Clinical DataRare DiseaseRead full story

Post navigation

Beam posts positive data on base editing treatment for AATD →
← Wave crashes on obesity drug update; Kodiak’s reboot pays dividends

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com